Saudi Arabia Animal Health Market Size, Share & Forecast, By Product Type, Animal Type & Distribution Channel, 2026-2031

The Saudi Arabia Animal Health Market was worth USD 459 million in 2025. The estimate covers veterinary pharmaceuticals, vaccines and biologics, diagnostics, medicated feed additives, and paid animal-health technologies sold to livestock, poultry, equine, camel and companion-animal customers. Demand is anchored by 22.1 million sheep, 7.3 million goats, 2.24 million camels, 516,000 cattle and an estimated 1.8 million pets. Pharmaceuticals remain the largest profit pool, while vaccines, molecular diagnostics and preventive-care platforms are expanding faster because they reduce outbreak losses and improve farm productivity.

The market is forecast to reach USD 665 million by 2031, expanding at a 6.37% CAGR during 2026-2031. Standardized treatment volume is projected to rise from 111.0 million units in 2025 to 149.0 million units in 2031, while value grows faster because spending shifts toward vaccines, biologics, molecular diagnostics and specialist therapies. The forecast assumes continued poultry and dairy investment, steady companion-animal formalization, improved disease surveillance and gradual local manufacturing. Regulatory delays or cold-chain disruption would reduce the pace, while successful vaccine localization would raise it.

The largest profit-pool shift will occur from episodic anti-infective treatment toward preventive biologics, diagnostics and contracted herd-health services. Preventive care is projected to rise from 45% of market value in 2025 to 52% in 2031. Vaccines gain from food-security policy and local-strain development, while molecular diagnostics capture value through recurring panels, rapid turnaround and production-loss avoidance. Digital monitoring also improves customer retention because suppliers can connect product use with measurable flock or herd outcomes. Conventional pharmaceuticals remain large, but their pricing power is comparatively constrained by generic competition.

Import dependence is the most important structural constraint. Approximately 70% of veterinary pharmaceuticals were imported in 2024, exposing the market to foreign production schedules, freight volatility, cold-chain failures and regulatory-document gaps. Biologics require validated temperature control, while full registration packages can delay launch beyond accelerated review timelines. The constraint is especially material for smaller farms and remote regions, where distributors face lower route density and higher inventory costs. Domestic manufacturing is improving, but advanced vaccines, proprietary therapeutics and molecular diagnostic platforms will remain externally sourced through much of the forecast period.

Saudi Arabia is the largest selected GCC animal-health market at USD 459 million in 2025, ahead of the UAE at USD 235 million, Qatar at USD 196 million, Kuwait at USD 190 million and Oman at USD 65 million. Its 6.37% forecast CAGR is lower than the UAE, Oman and Kuwait benchmarks but above Qatar. Saudi Arabia's advantage is demand density: more than 32 million livestock animals, large commercial poultry clusters and a government localization agenda. Its challenge is converting scale into faster growth through domestic manufacturing, specialist services and more efficient distribution.

Commercial poultry and livestock intensification has the strongest near-term impact because it creates high-frequency, protocol-driven demand for vaccines, diagnostics, parasiticides and biosecurity products. Broiler production reached 1.25 million tons in 2024, up 12.9% year on year, while table-egg production reached 8.4 billion units. Dairy output of 2.7 billion liters adds a separate recurring pool for mastitis, reproductive and metabolic health. Companion-animal demand grows faster from a smaller base, but production animals remain the core revenue anchor because disease events directly affect national food supply and farm economics.